121 related articles for article (PubMed ID: 11723043)
1. Cardiovascular news.
SoRelle R
Circulation; 2001 Nov; 104(22):E9053-5. PubMed ID: 11723043
[No Abstract] [Full Text] [Related]
2. [Drug therapy of ventricular arrhythmias - a contemporary perspective].
Grönefeld GC; Hohnloser SH
Dtsch Med Wochenschr; 2002 Oct; 127(43):2280-4. PubMed ID: 12397544
[No Abstract] [Full Text] [Related]
3. Ranolazine: a new approach to treating an old problem.
Reddy BM; Weintraub HS; Schwartzbard AZ
Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
[TBL] [Abstract][Full Text] [Related]
4. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
5. Azimilide. NE 10064, Stedicor.
Drugs R D; 1999 Apr; 1(4):297-300. PubMed ID: 10566048
[No Abstract] [Full Text] [Related]
6. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
Camm AJ; Pratt CM; Schwartz PJ; Al-Khalidi HR; Spyt MJ; Holroyde MJ; Karam R; Sonnenblick EH; Brum JM;
Circulation; 2004 Mar; 109(8):990-6. PubMed ID: 14967728
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
Pratt CM; Singh SN; Al-Khalidi HR; Brum JM; Holroyde MJ; Marcello SR; Schwartz PJ; Camm AJ;
J Am Coll Cardiol; 2004 Apr; 43(7):1211-6. PubMed ID: 15063432
[TBL] [Abstract][Full Text] [Related]
8. Azimilide for atrial fibrillation: clinical trial results and implications.
Pritchett EL; Marcello SR
Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
[TBL] [Abstract][Full Text] [Related]
9. [Conservative therapy of patients with stable coronary heart disease].
Custodis F; Laufs U
Herz; 2012 Feb; 37(1):85-96. PubMed ID: 22331062
[TBL] [Abstract][Full Text] [Related]
10. Pure class III agents for prevention of sudden cardiac death.
Pratt CM
J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine (Ranexa) for chronic stable angina.
Ndegwa S
Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
[TBL] [Abstract][Full Text] [Related]
13. The shocking story of azimilide.
Hanna IR; Langberg JJ
Circulation; 2004 Dec; 110(24):3624-6. PubMed ID: 15596558
[No Abstract] [Full Text] [Related]
14. Does ranolazine have a place in the treatment of acute coronary syndromes?
Newby LK; Peterson ED
JAMA; 2007 Apr; 297(16):1823-5. PubMed ID: 17456825
[No Abstract] [Full Text] [Related]
15. Expanding the understanding of the treatment of chronic angina: a 21st century approach-part II.
Conti CR
Clin Cardiol; 2008 Jul; 31(7):295-6. PubMed ID: 18636470
[TBL] [Abstract][Full Text] [Related]
16. Acute coronary syndromes: new developments in pharmacological treatment strategies.
Gylys K; Gold M
Crit Care Nurse; 2000 Apr; Suppl():3-14; quiz 15-6. PubMed ID: 11876169
[No Abstract] [Full Text] [Related]
17. [Intervention in ischemic heart disease and myocardial infarction. 3. Medical intervention].
Pedersen A
Ugeskr Laeger; 1982 Jul; 144(29):2156-64. PubMed ID: 6128809
[No Abstract] [Full Text] [Related]
18. Electrophysiology test may predict SCD (sudden cardiac death) risk: investigators induce VT in CAD patients.
Patient Focus Care Satisf; 1999 Aug; 7(8):94-5. PubMed ID: 10539529
[No Abstract] [Full Text] [Related]
19. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
Reiffel JA
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635
[No Abstract] [Full Text] [Related]
20. [Secondary prevention in the post-infarction period].
Corea L; Bentivoglio M
Cardiologia; 1989 Feb; 34(2):127-33. PubMed ID: 2567624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
